Form 4 for INAB IN8BIO, INC.
Accepted 2025-05-07 00:00:00 ET · period of report 2025-04-27 · accession 0001415889-25-012287 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-05-07 | 2025-04-30 | INAB | Roemer Alan S. | Dir | M - OptEx | $0.18 | +113.5K | 387.5K | +41% | +$20.4K |
| DM | 2025-05-07 | 2025-04-27 | INAB | Roemer Alan S. | Dir | A - Grant | — | +204.9K | 102.5K | New | — |
| DM | 2025-05-07 | 2025-04-30 | INAB | Roemer Alan S. | Dir | M - OptEx | $0.00 | -113.5K | 0 | -100% | $0 |
| DM | 2025-05-07 | 2025-04-27 | INAB | Roemer Alan S. | Dir | D - Sale to Iss | — | -204.9K | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-30 | M | A | 11,000 | $0.18 | 398,489 | D | — | — | |
| 2 | Common | Common Stock | 2025-04-30 | M | A | 102,459 | $0.18 | 387,489 | D | — | — | |
| 3 | Derivative | Series B Warrants (right to buy) | 2025-04-27 | A | A | 91,459 | — | 91,459 | D | $0.45 · — to 2028-12-13 | 91,459 Common Stock | (F4) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. (F2) Fully vested and exercisable. |
| 4 | Derivative | Series B Warrants (right to buy) | 2025-04-30 | M | D | 11,000 | $0.00 | 0 | D | $0.18 · — to 2025-05-02 | 11,000 Common Stock | (F2) Fully vested and exercisable. |
| 5 | Derivative | Series B Warrants (right to buy) | 2025-04-27 | A | A | 11,000 | — | 11,000 | D | $0.18 · — to 2025-05-02 | 11,000 Common Stock | (F4) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. (F2) Fully vested and exercisable. |
| 6 | Derivative | Series B Warrants (right to buy) | 2025-04-27 | D | D | 102,459 | — | 0 | D | $1.50 · — to 2028-12-13 | 102,459 Common Stock | (F4) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share and expiration date of December 13, 2028. In regards to 11,000 warrant shares, the exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. In regards to the remaining 91,459 warrant shares, the exercise price was reduced to $0.45 per share with no change to the expiration date. (F3) The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. (F2) Fully vested and exercisable. |
| 7 | Derivative | Series A Warrants (right to buy) | 2025-04-30 | M | D | 102,459 | $0.00 | 0 | D | $0.18 · — to 2025-05-02 | 102,459 Common Stock | (F2) Fully vested and exercisable. |
| 8 | Derivative | Series A Warrants (right to buy) | 2025-04-27 | A | A | 102,459 | — | 102,459 | D | $0.18 · — to 2025-05-02 | 102,459 Common Stock | (F1) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. (F2) Fully vested and exercisable. |
| 9 | Derivative | Series A Warrants (right to buy) | 2025-04-27 | D | D | 102,459 | — | 0 | D | $0.45 · — to 2025-10-04 | 102,459 Common Stock | (F1) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 and later amended on October 4, 2024 with an exercise price of $0.45 per share and expiration date of October 4, 2025. On April 27, 2025, the warrant's exercise price was reduced to $0.1844 per share and the warrant expiration date was amended to May 2, 2025. (F3) The reported securities are included within 102,459 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 102,459 shares of common stock. (F2) Fully vested and exercisable. |